Please login to the form below

Not currently logged in
Email:
Password:

non-steroidal therapy

This page shows the latest non-steroidal therapy news and features for those working in and with pharma, biotech and healthcare.

Roche out-licenses lebrikizumab rights to Dermira

Roche out-licenses lebrikizumab rights to Dermira

Other competition is also in the offing including GlaxoSmithKline's asthma therapy Nucala (mepolizumab) and non-steroidal anti-inflammatory tapinarof, which are both in mid-stage testing for atopic dermatitis, and

Latest news

  • FDA green light for Pfizer's eczema drug FDA green light for Pfizer's eczema drug

    Pfizer's blockbuster-in-waiting Eucrisa has been approved by the FDA for eczema, becoming the first non-steroidal therapy for the skin condition in more than 15 years.

  • Pfizer adds eczema drug with $5.2bn Anacor acquisition Pfizer adds eczema drug with $5.2bn Anacor acquisition

    Expands innovative products business with non-steroidal therapy Crisaborole. Pfizer has snapped up Californian biopharma company Anacor in a $5.2bn deal that gives it a late-stage eczema candidate. ... and if approved would be the first new non-steroidal

  • Novartis wins childhood arthritis indication for Ilaris in EU Novartis wins childhood arthritis indication for Ilaris in EU

    Ilaris gains a new indication as a monthly subcutaneous injection in patients aged two years and older who have not responded to therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and ... The approval] represents another significant milestone in

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics